| Identification | Back Directory | [Name]
3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]- | [CAS]
1187594-14-4 | [Synonyms]
Ilunocitinib
3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]- | [Molecular Formula]
C17H17N7O2S | [MOL File]
1187594-14-4.mol | [Molecular Weight]
383.43 |
| Chemical Properties | Back Directory | [density ]
1.69±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 250 mg/mL (652.01 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.66±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1)[1]. | [in vivo]
Ilunocitinib (0.6–0.8 mg/kg, p.o., once daily, up to 112 days) significantly reduces pruritus and skin lesion scores in the Oclacitinib-induced canine atopic dermatitis dog model[2]. | Animal Model: | Oclacitinib-induced canine atopic dermatitis (cAD) dog model[2] | | Dosage: | 0.6-0.8 mg/kg | | Administration: | Oral gavage (p.o.), once daily, up to 112 days | | Result: | Within 14 days：showed similar efficacy to Oclacitinib in reducing pruritus and skin lesions.
By day 28：continued to decrease PVAS scores which was increased in the Oclacitinib group.
From days 28 to 112: Caused that mean PVAS and CADESI-04 scores were significantly lower in the Ilunocitinib group than in the Oclacitinib group (p ≤ 0.003 and p ≤ 0.023).
At day 112: Caused that 77% of Ilunocitinib-treated dogs achieved clinical remission of pruritus (PVAS <2) compared to 53% in the Oclacitinib group. |
| [References]
[1] James D. Rodgers, et al. Azetidine and cyclobutane derivatives as jak inhibitors. Patent. WO2009114512A1.
[2] Forster S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Vet Dermatol. 2025 Jan 6. DOI:10.1111/vde.13319 |
|
|